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Abstract: The importance of the underlying local and systemic oxidative stress and inﬂ  ammation 
in chronic obstructive pulmonary disease (COPD) has long been established. In view of the lack 
of therapy that might inhibit the progress of the disease, there is an urgent need for a success-
ful therapeutic approach that, through affecting the pathological processes, will inﬂ  uence the 
subsequent issues in COPD management such as lung function, airway clearance, dyspnoea, 
exacerbation, and quality of life. N-acetylcysteine (NAC) is a mucolytic and antioxidant drug 
that may also inﬂ  uence several inﬂ  ammatory pathways. It provides the sulfhydryl groups and 
acts both as a precursor of reduced glutathione and as a direct reactive oxygen species (ROS) 
scavenger, hence regulating the redox status in the cells. The changed redox status may, in turn, 
inﬂ  uence the inﬂ  ammation-controlling pathways. Moreover, as a mucolytic drug, it may, by 
means of decreasing viscosity of the sputum, clean the bronchi leading to a decrease in dyspnoea 
and improved lung function. Nevertheless, as successful as it is in the in vitro studies and in vivo 
studies with high dosage, its actions at the dosages used in COPD management are debatable. 
It seems to inﬂ  uence exacerbation rate and limit the number of hospitalization days, however, 
with little or no inﬂ  uence on the lung function parameters. Despite these considerations and in 
view of the present lack of effective therapies to inhibit disease progression in COPD, NAC 
and its derivatives with their multiple molecular modes of action remain promising medication 
once doses and route of administration are optimized.
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Management issues in COPD 
Lung function, dyspnoea and quality of life
Chronic obstructive pulmonary disease (COPD) is a condition deﬁ  ned as a disease state 
characterized by airﬂ  ow limitation that is not fully reversible. The airﬂ  ow limitation 
is usually progressive and is associated with an abnormal inﬂ  ammatory response of 
lungs to noxious particles or gases, primarily caused by cigarette smoking (Celli et al 
2004). In Europe, COPD is ranked as the third most common cause of death (Pauwels 
et al 2001). 
The lung function and consequently patient quality of life worsens as disease 
progresses (Seemungal et al 1998; Hogg 2004). The standard way of assessing the 
progression of COPD (Burrows and Earle 1969) is an annual decline in forced expiratory 
volume in one second (FEV1), which is considered to be the best single correlate of 
mortality (Celli et al 2004) and is used as the main parameter in the evaluation of 
many other COPD aspects. In comparison with the normal subject where the FEV1 
decline reaches 20–30 mL/year, in COPD patients it reaches 60 mL/year (Anthonisen 
et al 1994). This accelerated decline in lung function is closely associated with an 
increased number of neutrophils in the sputum (Stanescu et al 1996) and hence with 
higher level of airway inﬂ  ammation. This, on the other hand, is proportional to the rise 
in the colonizing bacterial load as well as its changes (Wilkinson et al 2003). International Journal of COPD 2006:1(4) 426
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Cross-sectional studies have shown that quality of life 
deteriorates as lung function declines (Stahl et al 2005). 
Some groups, however, reported that the health status and 
health-related quality of life (HRQOL) do not strongly 
correlate with the lung function parameters such as FEV1 
(Antonelli-Inc et al 2003), but relate more to exercise per-
formance, mobility, and mortality (Jones et al 1989; Fan 
et al 2002). Since any improvement in physical perform-
ance relates to an improvement in quality of life scores and 
dyspnoea perception (Verrill et al 2005), the limitation of 
a functional status is considered very highly predictive of 
survival (ZuWallack et al 2004). Furthermore, dyspnoea 
correlates more closely with an impact on HRQOL than 
FEV1. Therefore, dyspnoea and HRQOL have become an 
important focus for therapy as dyspnoea is the predominant 
complaint for which patients with COPD seek medical 
attention (Hajiro et al 1999). 
Exacerbations
Patients with COPD are prone to periodic acute exacerba-
tions (AE) of their disease with worsening of the respiratory 
symptoms and inﬂ  ammatory parameters (Drost et al 2005). 
The frequency of these exacerbations varies, depending on the 
deﬁ  nition and severity (Wedzicha and Donaldson 2003). AE 
contributes to a diminished HRQOL and consequently to the 
reduced health status, frequent hospitalizations, and eventu-
ally increased morbidity (Donaldson et al 2002). Moreover, 
the exacerbations lead to the increased healthcare costs with 
exacerbations associated with a hospitalization accounting 
for 90% of the total costs of exacerbations (Oostenbrink and 
Rutten-van Molken 2004). 
Furthermore, the number of exacerbations per year 
correlates with disease severity (Siafakas et al 1995). An 
increased frequency of these episodes may hasten disease 
progression and accelerate the decline in the lung function 
since a physiologic recovery after an exacerbation is usually 
incomplete resulting in the decrease in quality of life and 
a tendency to future exacerbations (Donaldson et al 2002). 
Also more pronounced physiologic changes during AE are 
related to a longer exacerbation recovery time. Additionally, 
it has been reported that lung function together with health 
status are the most important risk factors for the re-admission 
that also relate to the psychological status of the patients 
(Gudmundsson et al 2005). Therefore the prevention of an 
acute exacerbation and improving the health status should 
be considered as one of the most important therapeutic 
targets.
Oxidative stress and inﬂ  ammation
There is increasing evidence that an oxidant/antioxidant 
imbalance, in favor of oxidants, occurs in COPD (Rahman et al 
1996; MacNee 2000). The main reason for this is cigarette 
smoke which is a complex mixture of more than 4700 chemi-
cal compounds, including high concentrations of free radicals 
and other oxidants (Church and Pryor 1985). Components of 
the lung matrix (eg, collagen, elastin) can be directly dam-
aged by the cigarette smoke (Cantin and Crystal 1985). In 
the breath, the oxidants generated by cigarette smoking or 
released from leukocytes and epithelial cells, are increased 
in stable patients and those with an acute exacerbation of 
COPD (Dekhuijzen et al 1996; Maziak et al 1998). There is 
also evidence that a systemic oxidative stress is present in the 
COPD patients. This is reﬂ  ected by an increased production 
of superoxide anion from the peripheral blood neutrophils 
in stable (Noguera et al 1998) and exacerbated COPD 
patients (Rahman et al 1996). Oxidative stress is inextricably 
linked to the inﬂ  ammatory response. It becomes clear that 
the inﬂ  ammatory process potentiates as COPD progresses 
(Hogg 2004) and exerts damage which is irreversible. This 
damage involves a complex remodeling process resulting 
in emphysema and ﬁ  brosis of the small airways. Tobacco 
smoking is not only a major source of the oxidants but is 
also a major factor initiating the local inﬂ  ammatory response 
(Churg et al 2002).
During acute exacerbation of COPD (AE), except for 
changes in the overall health status, there are differences 
observed in the inﬂ  ammatory and oxidative stress status of 
the patients. The increased number of inﬂ  ammatory cells and 
the accompanying elevated cytokine levels in stable COPD 
patients tend to rise even further during AE (Drost et al 2005), 
reﬂ  ecting the worsening of the underlying chronic inﬂ  amma-
tion in the lungs. These acute-upon-chronic episodes augment 
the damage exerted by chronic processes and may diminish 
the chances of full recovery. 
The management points in COPD are shown in Figure 1.
Role of mucolytics
For patients suffering from COPD, asthma, and cystic fibrosis, 
mucus hypersecretion is considered to be a risk factor for 
increased morbidity. While chronic mucus hypersecretion 
may not impair the lung function of the healthy individual, 
in a case of obstructive lung disorder, excessive mucus 
production accompanied by an inadequate mucus clearance 
may further hinder the air passage by clogging the already 
obstructed airways (Jeffery and Li 1997). The mucus is a International Journal of COPD 2006:1(4) 427
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complex mixture of proteins, lipids, water, and electrolytes 
(Snider et al 1984; Robinson et al 1989) that, under normal 
conditions, maintains the moisture of the airway epithelium. 
It is produced by goblet, mucous, and serous cells (Lundgren 
and Shelhamer 1990) and stored until a secretory signal is 
given. The mucus secretion may be stimulated by mediators 
produced by macrophages, lymphocytes, and epithelium 
(Cohan et al 1991; Gollub et al 1992). Furthermore, in the view 
that neutrophils are the key cells in COPD, there is emerging 
evidence that they play a key role in epidermal growth factor 
receptor (EGFR)-mediated mucin production through releas-
ing tumor necrosis factor-alpha (TNF-α) and hence inducing 
EGFR expression (Takeyama et al 1999; Kim and Nadel 
2004). Moreover, the differentiation of the mucus cells as well 
as secretion of the mucus from airway glands are induced by 
neutrophil elastase (Breuer et al 1987).
Nevertheless, by entrapping and removing foreign 
materials, the mucus forms a basic defense system of the res-
piratory system. In the large airways, mucus hypersecretion 
causes coughing and sputum production. In the peripheral 
airways, because of the smaller diameter, the formed mucus 
plugs are difﬁ  cult to remove and may block the peripheral 
airway completely. This, in turn, may result in gas trapping 
with increased total lung capacity (TLC) and decreased 
forced vital capacity (FVC). In COPD, mucus hypersecre-
tion is associated with disease exacerbation (Poole and Black 
2003), accelerated decline in FEV1 (Vestbo et al 1996) and 
inﬂ  ammatory cell inﬁ  ltration (Wedzicha and Donaldson 
2003). Moreover, the remaining sputum hinders the ac-
cessibility of inhaled medication to the peripheral airways. 
Therefore the mucus clearance and sterility maintenance 
are of importance in COPD. There is a large number of 
medications available that are meant to change the proper-
ties of airway secretion or block its production or release, 
or both. The mucolytics are responsible for the disruption 
of the mucous gel, generally by altering the degree of the 
cross-linking or the interactions between molecules in 
the gel. They include N-acetylcysteine (NAC) and related 
compounds, dornase–α, F-actin de-polymerizing agents 
and nondestructive mucolytics, like hypertonic saline and 
oligosaccharide agents and were previously reviewed (King 
and Rubin 2002).
Current treatments for COPD are symptomatic and focus 
on the bronchodilatation. No effective medication cur-
rently exists that may inﬂ  uence the progress of the disease. 
Therefore, mucolytics like NAC may form an interesting 
therapeutic approach. Classical mucolytics, like NAC and 
other thiol reducing agents, degrade the three-dimensional 
network that forms the mucus by reducing the disulphide 
bonds (S-S) to a sulfhydryl (SH) bond (-SH) that no longer 
participates in the cross-linking. They may act on the mucus 
elasticity and viscosity as well as modulate its production 
and secretion (Livingstone et al 1990; King and Rubin 2002). 
NAC has been reported to reduce the viscosity of sputum in 
both cystic ﬁ  brosis and COPD, facilitating the removal of 
pulmonary secretions (Ventresca et al 1989). Moreover, by 
maintaining the airway clearance, it prevents bacterial stimu-
lation of mucin production and hence mucus hypersecretion 
(Adler et al 1986).
NAC however, has also its disadvantages concern-
ing its accessibility of the peripheral airways and risk of 
bronchospasm in hyperreactive patients. Nevertheless, the 
superiority of NAC over the other mucolytics may be in its 
anti-inﬂ  ammatory and antioxidant properties and its muco-
lytic actions.
NAC: pharmacology 
and pharmacokinetics 
N-acetylcysteine is a thiol compound which has a chemical 
formula C5H9NO3S and a molecular weight of 163.2. It is 
rapidly absorbed following an oral dose of 600 mg with a 
peak of 4.6 μM after 60 min (Tsikas et al 1998). The plasma 
half-life has been reported to be 2.5 hours and no NAC is 
detectable 10–12 hours after administration (De Caro et al 
1989). It has been estimated that the oral bioavailability 
of the intact NAC molecule was about 10% (Borgstrom 
and Kagedal 1990). Following an oral dose, the majority 
of NAC is metabolized into another compound since ac-
companying increase in nonprotein and protein SH groups 
were found in plasma (Cotgreave, Berggren, et al 1987; De 
Caro et al 1989). Normalized maximal plasma concentration 
was reported to be signiﬁ  cantly higher after a 600 mg dose 
Figure 1 Management issues in COPD.
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than after a 200 mg dose. Moreover, increasing the dose also 
increased NAC bioavailability and time for maximal plasma 
concentration (Borgstrom and Kagedal 1990). Yet, higher 
concentration in plasma may be achieved after the intravenous 
administration (Prescott et al 1989; Crouch and Rusho 2005). 
During absorption, NAC is rapidly metabolized to cysteine, 
whose thiol group has reducing and antioxidant properties 
and which is a direct precursor of the glutathione. Because of 
its ability to reduce disulphide bounds, NAC is widely used 
to reduce viscosity and elasticity of the mucus (Aruoma et al 
1989). Moreover, NAC has the potential to interact directly 
with oxidants such as hydrogen peroxide, hydroxyl radical, 
and hypochloric acid (Aruoma et al 1989). To exert some 
effects in the lungs, concentration of NAC or its derivatives 
have to be sufﬁ  ciently elevated in bronchial epithelium or in 
epithelial lining ﬂ  uid. Nevertheless, no NAC was found in 
bronchoalveolar lavage ﬂ  uid (BALF) after 2 weeks of NAC 
intake (200 mg three times daily [tid]) by healthy volunteers 
(Cotgreave, Eklund, et al 1987).
Antioxidant properties
As a source of SH groups in cells, NAC can stimulate glu-
tathione (GSH) synthesis and play a role in the detoxiﬁ  cation 
(Kelly 1998) and play an important role in the antioxidant 
defense. However, when administered orally it fails to reach 
the desired concentration in the lungs as 600 mg/day did not 
alter cysteine and glutathione in BALF of healthy volunteers. 
However, it signiﬁ  cantly increased free and total plasma glu-
tathione and cysteine (Cotgreave, Eklund, et al 1987). When 
600 mg was administered to COPD patients an increase in 
plasma cysteine was observed with no difference in GSH 
levels. The higher dose was necessary (600 mg tid) in order 
to increase GSH levels in COPD patients (Bridgeman et al 
1994). This observation may suggest that under the condition 
of permanent oxidative stress, 600 mg may not be sufﬁ  cient 
to replenish the diminished GSH content. NAC can also act 
as direct scavenger of free radicals such as OH and H2O2 and 
O2 (Benrahmoune et al 2000) and it can protect against O2 
toxicity in the lung (Erzurum et al 1993). 
Anti-inﬂ  ammatory properties
Inﬂ  ammatory response is strongly inﬂ  uenced by redox-sensitive 
nuclear transcription factor-κB (NF-κB) which regulates a 
variety of pro-inﬂ  ammatory genes, and hence modulates the 
inﬂ  ammatory response (Desaki et al 2000). In vitro studies 
showed that a decrease in several inﬂ  ammatory mediators 
was related to NF-κB activity inhibition (Lappas et al 2003). 
Due to the fact that NAC modulates the cellular redox status, 
it can affect several pathways leading to decrease in NF-κB 
activity (Hutter and Greene 2000). Namely, NAC may 
affect thioredoxin and glutaredoxin expression which form 
other parts of ubiquitously expressed thiol-reducing system 
next to glutathione. Thioredoxin increases DNA binding of 
NF-κB by reducing cysteine of the p50 subunit (Matthews 
et al 1992) while glutaredoxin by sensing the changes in the 
redox state of GSH/GSSG may be involved in altering sig-
nal transduction pathways resulting in biological responses 
modulation (Song et al 2002). By decreasing the release of 
thioredoxin and glutaredoxin, NAC may attenuate NF-κB 
binding to DNA (Hoppe et al 2003; Nakamura H et al 1996) 
resulting in an impaired inﬂ  ammatory response (Peltoniemi 
et al 2004). Except from its effects on transcription factor 
NF-κB, NAC inﬂ  uences several signaling pathways such as 
p38, ERK1/2, SAPK/JNK, c-Jun, and c-Fos, among others 
(Wuyts et al 2003). Clinical application of NAC in different 
disorders as well as its molecular actions have been reviewed 
previously (Wuyts et al 2003; Zafarullah et al 2003).
Role of NAC in COPD
Lung function
N-acetylcysteine was reported to improve the lung function 
when administered for a longer period of time. Namely, Pela 
and colleagues (1999) reported a signiﬁ  cant improvement in 
FEV1 and maximal expiratory ﬂ  ow at 50% of forced vital 
capacity (MEF50) after 6 month treatment of stable COPD 
patients with NAC (600 mg/day). It supported the study of 
Aylward and colleagues (1980) who observed an improve-
ment from 25 to 30% FEV1 (% predicted) in the NAC-
treated group during the 4 weeks study period (Aylward 
et al 1980). On the other hand, several groups did not ﬁ  nd 
any changes in FEV1 and FVC although some reduction 
of hyperinﬂ  ation was obtained (Decramer et al 2005; van 
Overveld et al 2005).
Exacerbation
As far as exacerbations are concerned, in a recent literature 
review, Poole and Black (2003) found that regular use of 
mucolytics resulted in a signiﬁ  cant reduction of exacerbations 
by 0.07 exacerbation/month and reduction of illness days of 
0.56 days/month. Moreover, the study of Gerrits and col-
leagues (2003) found the correlation between the dose of NAC 
and the number of hospitalizations due to exacerbation. They 
concluded that NAC may decrease the risk of hospitalizations International Journal of COPD 2006:1(4) 429
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Table 1 Effects of NAC on clinical COPD outcomes
  Dose  Number   Study   FEV1 QOL  Dyspnea Exacerbation   Hospitalisa-  Side  Ref
     period        tion  /  effects
            sick  days 
400 mg  200 x 2  259  6 months  –  –  –  ⇓  ⇓ NO  12
600 mg  600 x 1  248  2 months  –  –  ⇓ –  –  23%x 93
  600 x 1  523  3 years  NS  NS  –  ⇓# –  NO  29
  600 x 1  169  6 months     Improve-   –  ⇓  ⇓ NS  73
        ment  in   
        cough
        severity 
  600 x 1  20  10 weeks  NS  –  –  –  –  NO  97
  300 x 2  116  6 months  –  –  –  ⇓ (NS)  ⇓ NO  79
  200 x 3  180  5 months  –  –  –  ⇓ (NS)    NS  1
  200 x 3  526  6 months  –  –  –  NS  ⇓ Well-  70
              tolerated 
  200 x 3  121  3 months  –  –  –  –  –  Well-  48
              tolerated 
1200 mg  600 x 2  153  22 weeks  NS  NS  –  ⇓ (NS)  –  NO  43
*1800 mg  600 x 3  9  4 days  –  –  –  –  –  NO  55
Note: *short duration COPD; #subgroup without ICS; xpercentage of patients suffering from side effects. 
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; ICS, inhaled corticosteroid; NAC, N-acetylcysteine; 
NO, no reported side effects; NS not signiﬁ  cantly different from placebo group–not reported; QOL, quality of life.
by about 30%. This reduction however needed minimal dose 
of 400 mg/day in order to reach protective effect (Gerrits 
et al 2003). It was also supported by study of Boman and 
colleagues (1983), who showed a reduction in exacerbation 
rate of 40%, which was signiﬁ  cantly different from 19% in 
placebo group. On the other hand, some studies only observed 
a trend towards a lower exacerbation rate (Parr and Huitson 
1987) or no effect at all (Rasmussen and Glennow 1988). 
Nevertheless, those studies reported a signiﬁ  cant reduction 
in a sick-leave days after 4 and 6 months of NAC treatment. 
The last large, 3-year study on NAC, the BRONCHUS trial, 
reported a signiﬁ  cant decrease in exacerbation rate only with 
no concomitant steroid therapy (Decramer et al 2005). The 
reports on NAC as add-on treatment during an acute exacer-
bation of COPD are scarce. The study of Black et al showed 
that the treatment of AE with NAC (600 mg twice daily) did 
not affect breathlessness, lung function, and oxygen satura-
tion (Black et al 2004). 
The mechanisms underlying the reduction in the number 
of exacerbations as well as the days of illness are not very well 
described. Because of the fact that no signiﬁ  cant increase in 
GSH level was found in plasma and BALF while using low 
dose (600 mg daily) higher dosages were necessary (600 mg 
tid) to obtain sustained effect on the thiols level in plasma, it 
seems unlikely that the changes induced by lower dose of NAC 
may alter the exacerbation rate or the course of exacerbations. 
On the other hand, NAC was reported to inﬂ  uence sputum 
cytokine level (van Overveld et al 2005) as well as sputum 
chemoattractant properties (van Overveld et al 2000). Because 
of the fact that a correlation between exacerbation frequency 
and sputum IL-6 and IL-8 levels exists (Bhowmik et al 2000), 
NAC, by acting on baseline level of those cytokines, may 
play a role in limiting the inﬂ  ammatory status and hence 
modulate the exacerbation frequency. Moreover, by decreas-
ing the viscosity of the sputum, it may facilitate the airway 
clearance and hence inﬂ  uence the course of the exacerbation, 
since there is a relationship between bacterial colonization and 
exacerbation frequency and character (Patel et al 2002). Effects 
of NAC on lung function and exacerbation rate are summarized in 
Table 1. The results from aforementioned reports indicate that 
low doses of NAC may have rather low antioxidant potential 
resulting in insigniﬁ  cant improvement of the lung function 
and limited inﬂ  uence on the exacerbation rate.
Inﬂ  ammation and oxidative 
stress in COPD
N-acetylcysteine has been reported to influence several 
factors that are involved in the modulation of the inﬂ  amma-
tory response. Namely, NAC decreased the chemoattractant 
properties of the sputum of COPD patients after 10 month International Journal of COPD 2006:1(4) 430
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treatment (van Overveld et al 2000) and modulated the 
inﬂ  ammatory response after 10 weeks of intake (Sadowska 
et al 2005). Moreover, in healthy volunteers it decreased the 
formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated 
respiratory burst and chemotaxis (Sadowska et al 2006). 
Furthermore, in the study of Urban and colleagues (1997), 
NAC improved the phagocytotic ability of neutrophils while 
decreasing their production of superoxide anion (SA) with no 
effects on migration already after 14 days of administration 
in healthy volunteers.
As far as oxidative stress is concerned, NAC decreased 
the exhaled H2O2 levels in COPD patients after long-term 
treatment (Kasielski and Nowak 2001; De Benedetto et al 
2005). Moreover, when administered to healthy volunteers, 
it increased the glutathione peroxidase activity (GPx) after 
2 weeks of oral treatment (Urban et al 1997) and increased 
thiol level after 30 min and 3 hours after administration 
(Szkudlarek et al 2004). 
It did not, however, inﬂ  uence GSH and cysteine level in 
BALF and lung tissue (Bridgeman et al 1994).
Furthermore supplementation with NAC (200 mg × 4/day for 
2 days + 800 mg on the test morning) increased the pre-exercise 
scavenging activity of healthy volunteer plasma (Sen et al 1994). 
When administered in higher doses (125 mg/kg) (intravenously) 
NAC signiﬁ  cantly increased GSH content and attenuated its 
decline during intense intermittent exercise and led to lesser 
glutathione disulﬁ  de (GSSG) formation (Medved et al 2003). 
These reports strongly suggest that for effective anti-
inﬂ  ammatory and antioxidant action, higher doses are necessary 
as the low NAC concentration (as also observed in vitro) was 
not found satisfactory (Sadowska et al 2007). This could be due 
to pharmacokinetics of NAC and administration route, which is 
far from optimal as it is unlikely to achieve desired concentra-
tion in the lung compartment (Bridgeman et al 1994). The novel 
route (eg, inhalation) is currently under investigation for both 
NAC and its derivatives and it is discussed in the last section.
Patient-focused perspectives 
Quality of life 
FEV1 hardly correlates with dyspnoea, which is closely related 
to the patient’s quality of life and which can vary among the pa-
tients with the same degree of the airway obstruction (Wolkove 
et al 1989). Dyspnoea, on the other hand, may reﬂ  ect more 
comprehensive information than airway obstruction in patients 
with COPD and should be taken into account while evaluating 
the successful treatment. NAC was reported to decrease the 
dyspnoea in COPD patients in comparison with placebo during 
the long-term treatment (Aylward et al 1980; Tattersall et al 
1984). This may be partly caused by the mucolytic effects of 
NAC leading to increase in the sputum volume and pourability. 
Moreover, an improvement in the subjects’ clinical state after 
NAC treatment has been noted (Jackson et al 1984) as well 
as an improvement of bronchitis-related symptoms (Stey et al 
2000) and increase in the patients’ well-being (Hansen et al 
1994). Furthermore, in study of Pela and colleagues (1999), 
65% of the treated patients reported improvement in quality 
of life in the NAC group (NAC on top of the current therapy) 
compared with 29% in placebo group. 
As far as the inﬂ  uence of NAC on physical activity is con-
cerned, it successfully improves the performance on fatiguing 
exercise when administered in high dosages. Namely, in the 
study by Matuszczak and colleagues (2005), at the oral dose of 
150 mg/kg, NAC delayed handgrip fatigue, increasing task per-
formance by one-third compared with the baseline. Similarly, in 
the study by Medved and colleagues (2004) (125 mg/kg intrave-
nously), NAC increased time to fatigue. Furthermore, the same 
dose was reported to inhibit fatigue of human skeletal muscles 
caused by repetitive, low-frequency electrical stimulation (Reid 
et al 1994). Moreover, high doses of NAC (600 mg × 3/day) 
prevented the exercise-induced increase in plasma thiobarbi-
turic reactive substances and O2 release and led to improved 
endurance time (Koechlin et al 2004). It may be suggested that 
NAC in high doses may act on GSH content replenishment and 
may increase the task performance and have positive effect on 
the physical activity and hence quality of life.
Compliance
The compliance is concerned to be better following the 600 mg/day 
regimen (Pela et al 1999). For example, in the BRONCHUS 
study, a compliance of 94% in the NAC group was observed 
in comparison with 92% in the placebo group (Decramer 
et al 2005). Nevertheless, a lower compliance observed at the 
regimen of 200 mg tid could be improved, following additional 
patient instructions (Parr and Huitson 1987). 
Tolerability and side-effects
NAC is generally safe. The oral dose of 600 mg/day or less 
is usually very well tolerated with no apparent side-effects 
and no impact on the patient satisfaction (Jackson et al 1984; International Journal of COPD 2006:1(4) 431
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rate, what leads to a direct (NAC treatment, AE management, 
hospitalization) and indirect (sick-leave days) cost 
reduction.
Conclusion: optimal usage, place in
therapy, and future perspectives
Based on the accessible literature, NAC in COPD has been 
studied mostly at rather low dosages with variable outcomes. 
The short-term, low-dose studies suggest that NAC may not 
be a drug of choice to enhance the GSH antioxidant potential 
of the lungs, since the effects are poor. While its effect on 
the oxidative stress markers seems to be inﬂ  uenced even 
at low dosages, the higher doses may ensure more rapid 
response. On the other hand, even long-term administration 
at low doses does not always have the anti-inﬂ  ammatory 
potential but substantially higher doses are necessary as in 
vitro studies have already demonstrated. As far as exacer-
bation rate, the number of sick-leave days and quality of 
life are concerned; the use of NAC seems to be promising 
as the majority of studies give favorable reports even at 
600 mg/day dose. 
Because of the fact that higher doses seem to be more 
effective in inﬂ  ammation and oxidative stress modulation 
with little side-effects, a change in the administration pattern 
may be of importance.
Furthermore, evaluating novel methods of drug delivery 
(inhaled NAC) (Szkudlarek et al 2004) and use of NAC deriva-
tives with better bioavailability may result in more effective 
treatment. For example, Nacystelyn (NAL), a lysine salt of 
NAC, has mucolytic and antioxidant properties. Its mucolytic 
activity is approximately equal to the sum of the activities of 
its two components, namely acetylcysteine and lysine, and 
its antioxidant properties are comparable with those of NAC 
(Van Antwerpen et al 2005). Moreover, because of its neutral 
pH, NAC can be delivered into the airways in inhaled form 
(Gillissen et al 1997; Antonicelli et al 2004). The inhaled form, 
tested in cystic ﬁ  brosis patients, was well tolerated and posi-
tively inﬂ  uenced airway mucus clearance (App et al 2002).
Another, newly developed form of NAC is N-acetylcysteine 
amide (NACA). Because of its neutral carboxyl group, NACA 
is lipophilic, cell permeating and has strong antioxidant and 
protective effects (Grinberg et al 2005). Nevertheless, more 
studies are necessary to assess the effectiveness of those 
derivatives in lung disorders in vivo.
Parr and Huitson 1987; Stey et al 2000). A dose of 1800 mg/day 
administered for a period of 4 days in COPD patients (Koechlin 
et al 2004) and for 5–6 weeks in the polycystic ovary syn-
drome was also well tolerated with no reported side-effects 
(Fulghesu et al 2002). Nevertheless, some trials mention 
some gastro-intestinal adverse reactions, which are not 
signiﬁ  cantly different from placebo group and comprise of 
dyspepsia, diarrhea or heartburn (Aylward et al 1980). In 
the last study of Matuszczak and colleagues (2005) where 
150 mg/kg of NAC was administered orally, mild reactions 
were reported in most of the patients (erythema, sweating, 
altered sensations, gastrointestinal disturbances). Except for 
gastrointestinal disturbances that persisted up to 4 hours and 
light-headedness which disappeared after 3 hours, the remain-
ing complaints disappeared 60 min after indigestion of NAC. 
The most common side-effects associated with high oral doses 
are nausea, vomiting, and other gastrointestinal disturbances, 
and therefore oral administration is contraindicated in persons 
with active peptic ulcer (Koo et al 1986). On the other hand, at 
low doses NAC may have a positive inﬂ  uence on the bacte-
rial colonization in gastritis (Huynh et al 2004). Infrequently, 
anaphylactic reactions after intravenous administration due to 
histamine release occur and can consist of rash, angioedema, 
bronchospasm, tachycardia, and changes in blood pressure 
(Tenenbein 1984).
Cost-effectiveness
High prevalence of COPD carries with it serious ﬁ  nancial 
consequences. According to the Belgisch Instituut voor 
Gezondheidseconomie, the costs of COPD increase together 
with the disease progression amounts to (in € /year/patient) 
2977€ for Stage I, 4740€ for Stage II, and 8565€ for Stage 
III, and IV (De Backer pers comm).
Disease severity, on the other hand, correlates with the 
number of exacerbations per year (Siafakas et al 1995). Since 
exacerbation is one of the important factors facilitating the 
progression of the disease and brings additional costs to the 
global expenditure, which are especially high in case of hos-
pitalization or intensive care unit admission (Niederman et al 
1999), effective exacerbation prevention could be the major 
cost-reducing factor. 
Grandjean and colleagues (2000) showed that NAC at 
dose 400 mg/day not only led to a signiﬁ  cant reduction in 
the number of exacerbations but also resulted in a smaller 
percentage of sick-leave days and lower hospitalization International Journal of COPD 2006:1(4) 432
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